Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study.

By N. Toma. Maedica, 2010

601 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. (2010, background): “s consistent with the time-dependent cumulative inhibition f ADP-induced platelet aggregation as observed with epeated daily dosing of clopidogrel and is further highighted by slow recovery of platelet function following drug ithdrawal (4,16,17).”
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi (2011, background): “Ticagrelor, an oral agent that binds reversibly to the latelet P2Y12 receptor, provides faster, more effective, and more consistent inhibition of platelet aggregation and more rapid recovery of platelet function after discontinuation than clopidogrel (534).”